Pierre-Emmanuel Rautou Selected Research

Budd-Chiari Syndrome (Budd Chiari Syndrome)

6/2020	Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome.
1/2018	Benign and malignant hepatocellular lesions in patients with vascular liver diseases.
11/2017	Reply to: "Calreticulin mutations and their importance in Budd-Chiari syndrome".
1/2017	Long-term Outcome and Analysis of Dysfunction of Transjugular Intrahepatic Portosystemic Shunt Placement in Chronic Primary Budd-Chiari Syndrome.
1/2012	Management of hepatic vascular diseases.
1/2011	Bleeding in patients with Budd-Chiari syndrome.
11/2009	Levels and initial course of serum alanine aminotransferase can predict outcome of patients with Budd-Chiari syndrome.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pierre-Emmanuel Rautou Research Topics

Disease

30	Fibrosis (Cirrhosis) 01/2022 - 01/2012
12	Portal Hypertension 08/2022 - 01/2011
12	Liver Diseases (Liver Disease) 01/2022 - 06/2014
10	Inflammation (Inflammations) 01/2022 - 08/2011
10	Ascites 12/2021 - 09/2010
9	Thrombosis (Thrombus) 01/2022 - 01/2012
7	Budd-Chiari Syndrome (Budd Chiari Syndrome) 06/2020 - 11/2009
7	Neoplasms (Cancer) 01/2019 - 07/2009
6	Hemorrhage 01/2022 - 07/2009
5	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 12/2010
4	Infections 01/2022 - 01/2018
4	End Stage Liver Disease 11/2021 - 05/2009
4	Atherosclerotic Plaque (Atheroma) 01/2017 - 10/2008
4	Alcoholic Hepatitis 01/2017 - 09/2014
3	Varicose Veins (Varicose Vein) 12/2021 - 10/2011
3	Alcoholic Liver Cirrhosis (Alcoholic Cirrhosis) 08/2021 - 01/2017
3	Hepatitis B 12/2020 - 09/2006
3	Liver Cirrhosis (Hepatic Cirrhosis) 01/2020 - 06/2015
3	Necrosis 01/2014 - 09/2008
2	Non-alcoholic Fatty Liver Disease 03/2022 - 01/2019
2	Cholestasis 10/2021 - 05/2007
2	Anorexia Nervosa 01/2020 - 09/2008
2	Starvation 01/2020 - 01/2014
2	Idiopathic Noncirrhotic Portal Hypertension 01/2019 - 01/2016
2	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 01/2019 - 09/2015
2	Hepatic Encephalopathy 01/2016 - 02/2015
2	Hypoxia (Hypoxemia) 01/2016 - 11/2011
2	Esophageal and Gastric Varices (Esophageal Varices) 02/2015 - 01/2011
2	Coinfection 09/2014 - 09/2006
2	Hyponatremia 08/2012 - 09/2010
2	Adenocarcinoma 11/2011 - 05/2007
1	COVID-19 01/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	Type 2 Diabetes Mellitus (MODY) 01/2022
1	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 01/2022
1	Liver Failure 01/2022
1	Metabolic Diseases (Metabolic Disease) 01/2022
1	Lymphopenia (Lymphocytopenia) 12/2021
1	Diabetes Mellitus 12/2021
1	Hepatitis A (Hepatitis, Infectious) 11/2021
1	Hepatitis 11/2021
1	Sclerosing Cholangitis 12/2020
1	Alcoholic Fatty Liver 12/2020
1	Acute Liver Failure (Fulminant Hepatic Failure) 12/2020
1	Liver Neoplasms (Liver Cancer) 12/2020
1	Ischemia 01/2020
1	Critical Illness (Critically Ill) 01/2020
1	Stroke (Strokes) 01/2020
1	Brain Hypoxia-Ischemia (Hypoxia Ischemia, Brain) 01/2020
1	Reperfusion Injury 01/2020
1	Hepatopulmonary Syndrome 01/2019

Drug/Important Bio-Agent (IBA)

8	Biomarkers (Surrogate Marker)IBA 01/2022 - 08/2011
4	Prothrombin (Factor II)IBA 01/2022 - 09/2008
4	4-(3-chlorophenylsulfanyl)piperidineIBA 10/2020 - 12/2018
4	Proteins (Proteins, Gene)FDA Link 01/2020 - 07/2009
4	CreatinineIBA 01/2019 - 05/2010
4	CytokinesIBA 09/2014 - 10/2008
3	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2014
3	SodiumIBA 12/2021 - 08/2012
3	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 08/2021 - 02/2011
2	Interleukin-6 (Interleukin 6)IBA 12/2021 - 01/2020
2	DiureticsIBA 12/2021 - 08/2012
2	SteroidsIBA 11/2021 - 01/2017
2	von Willebrand FactorIBA 08/2021 - 03/2015
2	RNA (Ribonucleic Acid)IBA 01/2020 - 09/2006
2	Beclin-1IBA 01/2020 - 12/2010
2	CalreticulinIBA 11/2017 - 01/2017
2	InterferonsIBA 01/2017 - 09/2006
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2015 - 07/2009
2	Alanine Transaminase (SGPT)IBA 11/2009 - 09/2008
1	Syntex adjuvant formulationIBA 03/2022
1	Transcription Factors (Transcription Factor)IBA 01/2022
1	eculizumab FDA Link 01/2022
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2022
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2022
1	Protein Isoforms (Isoforms)IBA 01/2022
1	insulin receptor-related receptor (IRR)IBA 01/2022
1	LigandsIBA 01/2022
1	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2021
1	Ointments (Pastes)IBA 10/2021
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 08/2021
1	E-SelectinIBA 08/2021
1	Contrast MediaIBA 06/2020
1	Carbon Tetrachloride (Tetrachloromethane)IBA 01/2020
1	gadobenic acid (gadobenate dimeglumine)FDA Link 01/2020
1	Cardiac GlycosidesIBA 01/2020
1	alpha2 Subunit Collagen Type IIBA 01/2020
1	Adenosine Triphosphatases (ATPase)IBA 01/2020
1	Proto-Oncogene Proteins c-sis (Platelet Derived Growth Factor B)IBA 01/2019
1	Vasodilator Agents (Vasodilators)IBA 01/2019

Therapy/Procedure

17	Therapeutics 01/2022 - 09/2006
7	Liver Transplantation 12/2021 - 01/2012
6	Surgical Portasystemic Shunt (Portosystemic Shunt) 07/2022 - 05/2009
5	Transjugular Intrahepatic Portasystemic Shunt 08/2022 - 05/2009
3	Stents 07/2022 - 01/2016
3	Transplantation 01/2020 - 06/2014
3	Ligation 05/2018 - 10/2008
2	Hematopoietic Stem Cell Transplantation 01/2019 - 09/2015
2	Drug Therapy (Chemotherapy) 01/2019 - 09/2015
1	Operative Surgical Procedures 01/2019